FTC Can't See Certain Docs In AbbVie Pay-For-Delay Row

A Georgia federal judge has allowed AbbVie, Actavis and other drugmakers facing pay-for-delay allegations involving patents for testosterone drug AndroGel to avoid disclosing most of a disputed set of documents to...

Already a subscriber? Click here to view full article